Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY MHLW Proposes New Premium with Easier-than-Sakigake Requirements to Fight Lag, Loss
November 13, 2023
-
REGULATORY Japan Panel Supports Certain Out-of-Pocket Payment for LLP-Generic Price Gap
November 10, 2023
-
ORGANIZATION PhRMA Chair Urges Japan to Maintain On-Patent Drug Prices, Improve Initial Pricing
November 10, 2023
-
BUSINESS Middle East Unrest Threatens Supply of Kaken’s Burn Eschar Remover
November 9, 2023
-
REGULATORY Health Minister Asks 24 Makers to Raise Production of Antitussives, Expectorants; Firms Want Regulatory, Pricing Steps
November 8, 2023
-
REGULATORY Govt to Support Shift to 24-Hour Production for Cough Drugs: Minister
November 8, 2023
-
BUSINESS Eisai CEO Confident of Achieving Leqembi Sales Goal of 10 Billion Yen in FY2023
November 8, 2023
-
BUSINESS Air Pollutant Might Be to Blame for NDMA Formation in Metformin: Towa Paper
November 7, 2023
-
BUSINESS Chugai Offloading Xeloda to Cheplapharm after German Firm Plants Flag in Japan
November 7, 2023
-
REGULATORY Health Minister to Make Direct Request to 24 Makers for Supply Ramp-Up
November 7, 2023
-
REGULATORY Japan PM Advisor Pushes Rethink of LLP Coverage to Reward Innovation, Pricing Debate without Taboos
November 6, 2023
-
REGULATORY Japan OKs New Economic Package; Startup, Pharma Promotion Embraced
November 6, 2023
-
REGULATORY Reward Innovation by Revisiting LLP Copay, Cut Doctor Fees: MOF
November 2, 2023
-
BUSINESS Sumitomo Eyes Return to Core Operating Profit in FY2024, Pruning Roivant Shares
November 1, 2023
-
BUSINESS 301 Employees Apply for Shionogi’s Voluntary Buyout Program
November 1, 2023
-
BUSINESS VLP Therapeutics Eyes Japan Filing of Next-Gen mRNA Vaccine in Mid-2024: CEO
October 31, 2023
-
REGULATORY No Objections to Reflecting Company Indices for Generic Supplies in Pricing: Chuikyo
October 30, 2023
-
REGULATORY Medical, Long-Term Care Data Linkage Holds Key to CEA: Leqembi Debate
October 30, 2023
-
BUSINESS Merck Sues Sawai over Januvia Generics Approved in Japan
October 27, 2023
-
ORGANIZATION Chuikyo Rep Interview 3-2 - Rengo Wants Substantive Discussions on Pricing System, Off-Year Revisions over Next Few Years
October 26, 2023
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…